Novel STAT5 Targets FasL in AML
Experts discuss miR-590, a novel STAT5 oncogenic miRNA that targets FasL in AML.
Diagnosis & Disease Information
AE Reporting Sensitivity Relatively Low in Cooperative Group Trials
The current system of AE reporting has modest sensitivity and a demonstrable false positive rate in cooperative group trials.
Biomarkers, AlloHSCT Predict Post-AML Relapse Prognosis
Cytogenetic and molecular abnormalities may also be prognostic of post-relapse prognosis.
Leukemia, B-cell Lymphoma Management Not Always Evidence Based
Clinical practices does not always reflect evidence-based expert opinion when it comes to management of acute or chronic myeloid leukemia (AML, CML) and B-cell lymphomas.
Ponatinib Shows Promise for Resistant Ph+ Leukemia
Ponatinib shows “early, deep and durable” molecular responses among patients with chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
FCR Chemoimmunotherapy Improved EFS in High-Risk, Early-Stage CLL
Fludarabine, cyclophosphamide and rituximab (FCR) chemoimmunotherapy is associated with improved event-free survival in patients with high-risk, early-stage CLL.
Oral IPI-145 PI3K Inhibitor Shows Promising Activity in Relapsed/Refractory CLL
Clinical activity has been observed in patients with relapsed/refractory CLL at all doses of IPI-145 studied, from 8 mg to 75 mg twice daily.
Novel Proteasome Inhibitor Elicits Response in Multiple Myeloma Patients
Ixazomib citrate plus lenalidomide/dexamethasone active in newly diagnosed multiple myeloma.
Gemtuzumab Ozogamicin Reduces Pediatric AML Relapse Risk
Adding gemtuzumab ozogamicin to standard therapy improved event-free survival improved in children with de novo acute myeloid leukemia.
Dendritic Cell Vaccine Prolongs Chemotherapy-induced AML Remission for Some Patients
Dendritic cell vaccination after chemotherapy-induced remission in acute myeloid leukemia has a “demonstrable” anti-relapse effect for some high-risk patient, according to data presented at ASH 2013.
- Loading...
Loading...
Loading... 
Loading...